APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rotavirus Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Rotavirus Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025181 pages

Choose your research edition.

Industry ResearchRotavirus Infections Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Rotavirus Infections Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Rotavirus Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rotavirus Infections Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Rotavirus Infections Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Rotavirus Infections Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Rotavirus Infections Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Rotavirus Infections Drug include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rotavirus Infections Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rotavirus Infections Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rotavirus Infections Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rotavirus Infections Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Rotavirus Infections Drug Segment by Company

Wuhan Institute of Biological Products Co Ltd

Beijing Minhai Biotechnology Co Ltd

UMN Pharma Inc

Serum Institute of India Ltd

Nanotherapeutics Inc

Medicago Inc

Curevac AG

Biological E Ltd

Bharat Biotech International Ltd

Rotavirus Infections Drug Segment by Type

UMN-2001

RV-625

RV-3BB

Rotavac-5C

Others

Rotavirus Infections Drug Segment by Application

Clinic

Hospital

Others

Rotavirus Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rotavirus Infections Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Rotavirus Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Rotavirus Infections Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Rotavirus Infections Drug Industry Trends Table 2. Rotavirus Infections Drug Industry Drivers Table 3. Rotavirus Infections Drug Industry Opportunities and Challenges Table 4. Rotavirus Infections Drug Industry Restraints Table 5. Global Rotavirus Infections Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Rotavirus Infections Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Rotavirus Infections Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Rotavirus Infections Drug Sales Market Share by Manufacturers Table 9. Global Rotavirus Infections Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Rotavirus Infections Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Rotavirus Infections Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Rotavirus Infections Drug Manufacturers, Product Type & Application Table 13. Global Rotavirus Infections Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Rotavirus Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of UMN-2001 Table 17. Major Manufacturers of RV-625 Table 18. Major Manufacturers of RV-3BB Table 19. Major Manufacturers of Rotavac-5C Table 20. Major Manufacturers of Others Table 21. Global Rotavirus Infections Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Rotavirus Infections Drug Sales by Type (2021-2026) & (k units) Table 23. Global Rotavirus Infections Drug Sales by Type (2027-2032) & (k units) Table 24. Global Rotavirus Infections Drug Sales Market Share by Type (2021-2026) Table 25. Global Rotavirus Infections Drug Sales Market Share by Type (2027-2032) Table 26. Global Rotavirus Infections Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Rotavirus Infections Drug Revenue by Type (2021-2026) & (k units) Table 28. Global Rotavirus Infections Drug Revenue by Type (2027-2032) & (k units) Table 29. Global Rotavirus Infections Drug Revenue Market Share by Type (2021-2026) Table 30. Global Rotavirus Infections Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Rotavirus Infections Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Rotavirus Infections Drug Sales by Application (2021-2026) & (k units) Table 36. Global Rotavirus Infections Drug Sales by Application (2027-2032) & (k units) Table 37. Global Rotavirus Infections Drug Sales Market Share by Application (2021-2026) Table 38. Global Rotavirus Infections Drug Sales Market Share by Application (2027-2032) Table 39. Global Rotavirus Infections Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Rotavirus Infections Drug Revenue by Application (2021-2026) & (k units) Table 41. Global Rotavirus Infections Drug Revenue by Application (2027-2032) & (k units) Table 42. Global Rotavirus Infections Drug Revenue Market Share by Application (2021-2026) Table 43. Global Rotavirus Infections Drug Revenue Market Share by Application (2027-2032) Table 44. Global Rotavirus Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Rotavirus Infections Drug Sales by Region (2021-2026) & (k units) Table 46. Global Rotavirus Infections Drug Sales Market Share by Region (2021-2026) Table 47. Global Rotavirus Infections Drug Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Rotavirus Infections Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 51. North America Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 52. Europe Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 54. Europe Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Rotavirus Infections Drug Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Rotavirus Infections Drug Sales by Country (2027-2032) & (k units) Table 61. Global Rotavirus Infections Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Rotavirus Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Rotavirus Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Rotavirus Infections Drug Revenue Market Share by Region (2021-2026) Table 65. Global Rotavirus Infections Drug Revenue Market Share by Region (2027-2032) Table 66. Wuhan Institute of Biological Products Co Ltd Company Information Table 67. Wuhan Institute of Biological Products Co Ltd Business Overview Table 68. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio Table 70. Wuhan Institute of Biological Products Co Ltd Recent Development Table 71. Beijing Minhai Biotechnology Co Ltd Company Information Table 72. Beijing Minhai Biotechnology Co Ltd Business Overview Table 73. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio Table 75. Beijing Minhai Biotechnology Co Ltd Recent Development Table 76. UMN Pharma Inc Company Information Table 77. UMN Pharma Inc Business Overview Table 78. UMN Pharma Inc Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. UMN Pharma Inc Rotavirus Infections Drug Product Portfolio Table 80. UMN Pharma Inc Recent Development Table 81. Serum Institute of India Ltd Company Information Table 82. Serum Institute of India Ltd Business Overview Table 83. Serum Institute of India Ltd Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio Table 85. Serum Institute of India Ltd Recent Development Table 86. Nanotherapeutics Inc Company Information Table 87. Nanotherapeutics Inc Business Overview Table 88. Nanotherapeutics Inc Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio Table 90. Nanotherapeutics Inc Recent Development Table 91. Medicago Inc Company Information Table 92. Medicago Inc Business Overview Table 93. Medicago Inc Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Medicago Inc Rotavirus Infections Drug Product Portfolio Table 95. Medicago Inc Recent Development Table 96. Curevac AG Company Information Table 97. Curevac AG Business Overview Table 98. Curevac AG Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Curevac AG Rotavirus Infections Drug Product Portfolio Table 100. Curevac AG Recent Development Table 101. Biological E Ltd Company Information Table 102. Biological E Ltd Business Overview Table 103. Biological E Ltd Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Biological E Ltd Rotavirus Infections Drug Product Portfolio Table 105. Biological E Ltd Recent Development Table 106. Bharat Biotech International Ltd Company Information Table 107. Bharat Biotech International Ltd Business Overview Table 108. Bharat Biotech International Ltd Rotavirus Infections Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio Table 110. Bharat Biotech International Ltd Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Rotavirus Infections Drug Distributors List Table 114. Rotavirus Infections Drug Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Rotavirus Infections Drug Product Image Figure 2. Global Rotavirus Infections Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rotavirus Infections Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Rotavirus Infections Drug Sales (2021-2032) & (k units) Figure 5. Global Rotavirus Infections Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Rotavirus Infections Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. UMN-2001 Image Figure 9. RV-625 Image Figure 10. RV-3BB Image Figure 11. Rotavac-5C Image Figure 12. Others Image Figure 13. Global Rotavirus Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Rotavirus Infections Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Rotavirus Infections Drug Sales Market Share by Type (2021-2032) Figure 16. Global Rotavirus Infections Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Rotavirus Infections Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Rotavirus Infections Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Rotavirus Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Rotavirus Infections Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Rotavirus Infections Drug Sales Market Share by Application (2021-2032) Figure 25. Global Rotavirus Infections Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Rotavirus Infections Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Rotavirus Infections Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 42. China Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Rotavirus Infections Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Rotavirus Infections Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Rotavirus Infections Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Rotavirus Infections Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Rotavirus Infections Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Rotavirus Infections Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Rotavirus Infections Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Rotavirus Infections Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Rotavirus Infections Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Rotavirus Infections Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • UMN-2001
  • RV-625
  • RV-3BB
  • Rotavac-5C
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Wuhan Institute of Biological Products Co Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • UMN Pharma Inc
  • Serum Institute of India Ltd
  • Nanotherapeutics Inc
  • Medicago Inc
  • Curevac AG
  • Biological E Ltd
  • Bharat Biotech International Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rotavirus Infections Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rotavirus Infections Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Rotavirus Infections Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Rotavirus Infections Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Rotavirus Infections Drug Market Dynamics
  1. 2.1 Rotavirus Infections Drug Industry Trends
  2. 2.2 Rotavirus Infections Drug Industry Drivers
  3. 2.3 Rotavirus Infections Drug Industry Opportunities and Challenges
  4. 2.4 Rotavirus Infections Drug Industry Restraints
3 Rotavirus Infections Drug Market by Manufacturers
  1. 3.1 Global Rotavirus Infections Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Rotavirus Infections Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Rotavirus Infections Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Rotavirus Infections Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Rotavirus Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Rotavirus Infections Drug Manufacturers, Product Type & Application
  7. 3.7 Global Rotavirus Infections Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Rotavirus Infections Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Rotavirus Infections Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Rotavirus Infections Drug Tier 1, Tier 2, and Tier 3
4 Rotavirus Infections Drug Market by Type
  1. 4.1 Rotavirus Infections Drug Type Introduction
  2. 4.1.1 UMN-2001
  3. 4.1.2 RV-625
  4. 4.1.3 RV-3BB
  5. 4.1.4 Rotavac-5C
  6. 4.1.5 Others
  7. 4.2 Global Rotavirus Infections Drug Sales by Type
  8. 4.2.1 Global Rotavirus Infections Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Rotavirus Infections Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Rotavirus Infections Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Rotavirus Infections Drug Revenue by Type
  12. 4.3.1 Global Rotavirus Infections Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Rotavirus Infections Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Rotavirus Infections Drug Revenue Market Share by Type (2021-2032)
5 Rotavirus Infections Drug Market by Application
  1. 5.1 Rotavirus Infections Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Rotavirus Infections Drug Sales by Application
  6. 5.2.1 Global Rotavirus Infections Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Rotavirus Infections Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Rotavirus Infections Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Rotavirus Infections Drug Revenue by Application
  10. 5.3.1 Global Rotavirus Infections Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Rotavirus Infections Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Rotavirus Infections Drug Revenue Market Share by Application (2021-2032)
6 Global Rotavirus Infections Drug Sales by Region
  1. 6.1 Global Rotavirus Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rotavirus Infections Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Rotavirus Infections Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Rotavirus Infections Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Rotavirus Infections Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Rotavirus Infections Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Rotavirus Infections Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Rotavirus Infections Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Rotavirus Infections Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Rotavirus Infections Drug Revenue by Region
  1. 7.1 Global Rotavirus Infections Drug Revenue by Region
  2. 7.1.1 Global Rotavirus Infections Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Rotavirus Infections Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Rotavirus Infections Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Rotavirus Infections Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Rotavirus Infections Drug Revenue (2021-2032)
  8. 7.2.2 North America Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Rotavirus Infections Drug Revenue (2021-2032)
  11. 7.3.2 Europe Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Rotavirus Infections Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Rotavirus Infections Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Rotavirus Infections Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Wuhan Institute of Biological Products Co Ltd
  2. 8.1.1 Wuhan Institute of Biological Products Co Ltd Company Information
  3. 8.1.2 Wuhan Institute of Biological Products Co Ltd Business Overview
  4. 8.1.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
  6. 8.1.5 Wuhan Institute of Biological Products Co Ltd Recent Developments
  7. 8.2 Beijing Minhai Biotechnology Co Ltd
  8. 8.2.1 Beijing Minhai Biotechnology Co Ltd Company Information
  9. 8.2.2 Beijing Minhai Biotechnology Co Ltd Business Overview
  10. 8.2.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
  12. 8.2.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
  13. 8.3 UMN Pharma Inc
  14. 8.3.1 UMN Pharma Inc Company Information
  15. 8.3.2 UMN Pharma Inc Business Overview
  16. 8.3.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
  18. 8.3.5 UMN Pharma Inc Recent Developments
  19. 8.4 Serum Institute of India Ltd
  20. 8.4.1 Serum Institute of India Ltd Company Information
  21. 8.4.2 Serum Institute of India Ltd Business Overview
  22. 8.4.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
  24. 8.4.5 Serum Institute of India Ltd Recent Developments
  25. 8.5 Nanotherapeutics Inc
  26. 8.5.1 Nanotherapeutics Inc Company Information
  27. 8.5.2 Nanotherapeutics Inc Business Overview
  28. 8.5.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
  30. 8.5.5 Nanotherapeutics Inc Recent Developments
  31. 8.6 Medicago Inc
  32. 8.6.1 Medicago Inc Company Information
  33. 8.6.2 Medicago Inc Business Overview
  34. 8.6.3 Medicago Inc Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Medicago Inc Rotavirus Infections Drug Product Portfolio
  36. 8.6.5 Medicago Inc Recent Developments
  37. 8.7 Curevac AG
  38. 8.7.1 Curevac AG Company Information
  39. 8.7.2 Curevac AG Business Overview
  40. 8.7.3 Curevac AG Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Curevac AG Rotavirus Infections Drug Product Portfolio
  42. 8.7.5 Curevac AG Recent Developments
  43. 8.8 Biological E Ltd
  44. 8.8.1 Biological E Ltd Company Information
  45. 8.8.2 Biological E Ltd Business Overview
  46. 8.8.3 Biological E Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biological E Ltd Rotavirus Infections Drug Product Portfolio
  48. 8.8.5 Biological E Ltd Recent Developments
  49. 8.9 Bharat Biotech International Ltd
  50. 8.9.1 Bharat Biotech International Ltd Company Information
  51. 8.9.2 Bharat Biotech International Ltd Business Overview
  52. 8.9.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
  54. 8.9.5 Bharat Biotech International Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rotavirus Infections Drug Value Chain Analysis
  2. 9.1.1 Rotavirus Infections Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rotavirus Infections Drug Production Mode & Process
  6. 9.2 Rotavirus Infections Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rotavirus Infections Drug Distributors
  9. 9.2.3 Rotavirus Infections Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst